Modulation of Lonp1 Activity by Small Compounds
Biomolecules · 2025
DOI: 10.3390/biom15040553 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biomolecules, 2025. Verfasst von Giada Zanini und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Life Sciences, University of Modena and Reggio Emilia, 41125 Modena, Italy. Hauptthemen laut MEDLINE: Mitochondrial Proteins, ATP-Dependent Proteases, Small Molecule Libraries. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 120 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Italian Association for Cancer Research, AIRC.
Abstract (Originalsprache)
The Lon protease homolog 1 (LONP1) is an ATP-dependent mitochondrial protease essential for maintaining proteostasis, bioenergetics, and cellular homeostasis. LONP1 plays a pivotal role in protein quality control, mitochondrial DNA maintenance, and oxidative phosphorylation system (OXPHOS) regulation, particularly under stress conditions. Dysregulation of LONP1 has been implicated in various pathologies, including cancer, metabolic disorders, and reproductive diseases, positioning it as a promising pharmacological target. This review examines compounds that modulate LONP1 activity, categorizing them into inhibitors and activators. Inhibitors such as CDDO and its derivatives selectively target LONP1, impairing mitochondrial proteolysis, inducing protein aggregation, and promoting apoptosis, particularly in cancer cells. Compounds like Obtusilactone A and proteasome inhibitors (e.g., MG262) demonstrate potent cytotoxicity, further expanding the therapeutic landscape. Conversely, LONP1 activators, including Artemisinin derivatives and 84-B10, restore mitochondrial function and protect against conditions such as polycystic ovary syndrome (PCOS) and acute kidney injury (AKI). Future research should focus on improving the specificity, bioavailability, and pharmacokinetics of these modulators. Advances in structural biology and drug discovery will enable the development of novel LONP1-targeted therapies, addressing diseases driven by mitochondrial dysfunction and proteostasis imbalance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Life Sciences, University of Modena and Reggio Emilia, 41125 Modena, Italy.
- National Institute for Cardiovascular Research-INRC, 40126 Bologna, Italy.
- Department of Quality-of-Life Sciences, University of Bologna, 40126 Bologna, Italy.
- Department of Surgical, Medical, Dental and Morphological Sciences, University of Modena and Reggio Emilia, 41125 Modena, Italy.
- Department of Pharmacy-Pharmaceutical Sciences, University of Bari "Aldo Moro", 70125 Bari, Italy.
ORCID-Profile: Giada Zanini, Anna Vittoria Mattioli, Milena Nasi, Ciro Leonardo Pierri, Marcello Pinti
Förderung
- Italian Association for Cancer Research
- AIRC
Zitieren
APA
Zanini, G., Micheloni, G., Sinigaglia, G., Selleri, V., Mattioli, A. V., Nasi, M., Pierri, C. L., & Pinti, M. (2025). Modulation of Lonp1 Activity by Small Compounds. Biomolecules. https://doi.org/10.3390/biom15040553
Vancouver
Zanini G, Micheloni G, Sinigaglia G, Selleri V, Mattioli AV, Nasi M, et al. Modulation of Lonp1 Activity by Small Compounds. Biomolecules. 2025. doi:10.3390/biom15040553
BibTeX
@article{Zanini2025,
author = {Zanini, Giada and Micheloni, Giulia and Sinigaglia, Giorgia and Selleri, Valentina and Mattioli, Anna Vittoria and Nasi, Milena and Pierri, Ciro Leonardo and Pinti, Marcello},
title = {Modulation of Lonp1 Activity by Small Compounds},
journal = {Biomolecules},
year = {2025},
doi = {10.3390/biom15040553}
}
EUVIMED